Related Experiment Videos
Effect of a beta3-adrenergic agonist on liver glucokinase gene expression in alloxan-diabetic rats
F I Milagro1, J Gómez-Ambrosi, E Martínez-Ansó
1Departamento de Fisiología y Nutrición, Universidad de Navarra, Pamplona, Spain.
Abstract:
Beta-adrenergic agonists have been shown to elicit powerful hypoglycemic effects when administered to different animal models of diabetes. However, the intimate mechanism involved in this process remains unclear. In this context, treatment of alloxan-induced diabetic rats with the beta3-adrenergic agonist Trecadrine (1 mg x kg(-1) x day(-1), s. c.) for four days, normalized glycemia with no changes in plasma insulin levels. Liver glucokinase, a key enzyme in the regulation of glucose storage in hepatocytes, whose gene expression is significantly decreased in alloxan-diabetic rodents, showed a recovery in its mRNA levels after Trecadrine administration. These data suggest that beta3-adrenergic agonists enhance glucose storage in liver, probably through a non-insulin dependent mechanism of action.
Insights
Beta3-adrenergic agonists like Trecadrine normalize blood sugar in diabetic rats. This occurs by enhancing liver glucose storage, independent of insulin levels.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Research
Background:
- Beta-adrenergic agonists demonstrate significant hypoglycemic effects in animal models of diabetes.
- The precise mechanism underlying these glucose-lowering effects remains incompletely understood.
Purpose of the Study:
- To investigate the mechanism by which beta3-adrenergic agonists, specifically Trecadrine, affect glucose metabolism in diabetic rats.
- To determine if Trecadrine influences insulin levels or hepatic glucose regulatory enzymes.
Main Methods:
- Alloxan-induced diabetic rats were treated subcutaneously with the beta3-adrenergic agonist Trecadrine (1 mg/kg/day) for four days.
- Plasma glucose and insulin levels were measured.
- Liver glucokinase mRNA levels, a key enzyme in glucose storage, were analyzed.
Main Results:
- Trecadrine treatment normalized glycemia in diabetic rats.
- No significant changes in plasma insulin levels were observed.
- Trecadrine administration led to a recovery of liver glucokinase mRNA levels, which were reduced in diabetic controls.
Conclusions:
- Beta3-adrenergic agonists, exemplified by Trecadrine, enhance hepatic glucose storage.
- This glucose-lowering effect appears to operate via a non-insulin-dependent mechanism.
- The findings suggest a potential therapeutic role for beta3-adrenergic agonists in managing diabetes through improved liver glucose regulation.